SCHEMBL22290812

SCHEMBL22290812

CC1CN(c2cc(Br)ccn2)CC(C)O1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 8/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.45
▸ PIK3CD O00329 2/20 0.44
▸ PIK3CA P42336 2/20 0.44
▸ PIK3CB P42338 2/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ ACACB O00763 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ PIK3CG P48736 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ WNT1 P04628 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29889142 1.00 LRRK2 (0.46) LRRK2KMT2ATDP1PIK3CDPIK3CA
SCHEMBL22290811 1.00 LRRK2 (0.46) LRRK2KMT2ATDP1PIK3CDPIK3CA
SCHEMBL30729441 1.00 LRRK2 (0.46) LRRK2KMT2ATDP1PIK3CDPIK3CA
SCHEMBL4550904 0.81 TDP1 (0.58) LRRK2KMT2ATDP1PIK3CDPIK3CA
SCHEMBL2725997 0.81 TDP1 (0.58) LRRK2KMT2ATDP1PIK3CDPIK3CA
SCHEMBL23860614 0.81 NMT1 (0.46) LRRK2KMT2AHTTACACB
SCHEMBL31400968 0.81 KDM4E (0.50) LRRK2KMT2ATDP1PIK3CDPIK3CA
SCHEMBL2726000 0.81 TDP1 (0.58) LRRK2KMT2ATDP1PIK3CDPIK3CA
SCHEMBL28402936 0.81 LRRK2 (0.47) LRRK2KMT2ATDP1PIK3CDPIK3CA
SCHEMBL21812486 0.78 ACACB (0.45) LRRK2KMT2APIK3CAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 — — CN disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 — — EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 — — CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB LRRK2 1680/4885KMT2A 792/4885TDP1 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback